A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
Open Access
- 1 April 2020
- journal article
- review article
- Published by Elsevier BV in Journal of Virus Eradication
- Vol. 6 (2), 45-51
- https://doi.org/10.1016/s2055-6640(20)30016-9
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control StudyEngineering, 2020
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)Nature Reviews Drug Discovery, 2020
- Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus InfectionThe Journal of Infectious Diseases, 2019
- Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational StudyThe Journal of Infectious Diseases, 2019
- Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)—Sierra Leone, 2014Clinical Infectious Diseases, 2016
- Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in GuineaPLoS Medicine, 2016
- Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adultsInternational journal of clinical pharmacology and therapeutics, 2015
- Safety of Oseltamivir in PregnancyDrug Safety, 2010
- Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressantsEuropean Neuropsychopharmacology, 2009